The rise of copyright’s blockbuster initially drove a boom for pharma, nevertheless recent shifts present a murky picture for those considering a stake. Off-patent alternatives are eating into profits, and ongoing legal battles add additional difficulty to the equation. While certain companies may still gain from complementary products, the overa